Business
Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States
BOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented
About this update from Sonoma Pharmaceuticals, Inc.
[{"type":"text","content":"BOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into a distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in the United States.The agreement provides for the distribution of Sonoma's wound care products through an existing and extensive network of hospital systems and other healthcare channels in the United States.\"This partnership represents a huge step forward in the expansion of our wound care business in the United States,\" said Amy Trombly, CEO of Sonoma. \"We are looking forward to working with a leading U.S.-based healthcare company, whose extensive distribution network will bring the benefits of our Microcyn technology to hospitals and other healthcare settings across the country.\"Further information about the partnership can be found in the Current Report on Form 8-K filed by Sonoma with the U.S. Securities and Exchange Commission on August 21, 2024.About Sonoma Pharmaceuticals, Inc.Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected] Statement...